N/A N=44 Uniting Couples in the Treatment of Binge-Eating Disorder
Binge-Eating Disorder
Primary: Number of Modified Intent-to-Treat Patients With Binge-eating Abstinence — 2; 1; 5; 4 Participants — p=0.36
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=647 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Carcinoma, Non-Small-Cell Lung · Carcinoma, Small Cell Lung · Carcinoma, Thymic
Primary: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality — 28.5; 44.2; 0; 24.9 percentage of participants
Phase 2 N=76 Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension
Chronic Thromboembolic Pulmonary Hypertension
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 72 Participants
N/A N=75 Pharmacogenomic Testing in Primary Care
Antidepressants Causing Adverse Effects in Therapeutic Use
Primary: Count of Participants Prescribed Antidepressant Medication — 5; 8; 5; 8 Participants
N/A N=122 Closed Incision Negative Pressure Therapy vs Standard of Care
Wound Complication
Primary: Prevalence of Wound Complications — 5; 11 Participants
N/A N=22 Alternative Exercise Program to Improve Skeletal Muscle Function and Fatigue in Cancer Survivors
Breast Cancer
Primary: Maximal Calcium-activated Tension Single Muscle Fiber Tension — 185; 172; 172; 168 milliNewtons per millimeter^2
Phase 2 N=102 Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS
COVID-19 · ARDS
Primary: Evaluation of 60-day Mortality Rate — 10; 14; 16 Participants — p=0.1343
Phase 2 N=59 Ganaxolone Treatment in Children With Fragile X Syndrome
Fragile x Syndrome
Primary: Clinical Global Impression-Improvement (CGI-I) Scale — 3.4; 3.5 Scores on a scale — p=0.4475
Phase 4 N=7 MEthylene Blue In Patients With Acquired Methemoglobinemia
Acquired Methaemoglobinaemia
Primary: Primary Efficacy Endpoint: Number of Participants With and Without 50% Reduction in metHb Level — 3; 3 Participants
Phase 3 N=29 Extended Release Tacrolimus vs. Twice-Daily Tacrolimus
End Stage Renal Disease · Rejection of Renal Transplant
Primary: Change in Kidney Transplant Function From 2 Weeks Post Transplant Through 12 Months Post Transplant — 2.03; -2.19 mL/min/1.73m^2
Phase 2 N=24 A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease
Sialorrhoea
Primary: Saliva Secreted Rate — -6.508; -34.512; 83.695; 7.414 percentage of change from baseline
Phase 3 N=1,101 Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Metastatic Prostate Cancer
Primary: Investigator-assessed Radiographic Progression-free Survival (rPFS), Per Prostate Cancer Working Group 3 (PCWG3) Criteria in Phosphatase and Tensin Homolog (PTEN) Loss…
N/A N=101 A Study of t:Slim X2 With Control-IQ Technology
Type 1 Diabetes Mellitus
Primary: Continuous Glucose Monitor (CGM)-Measured Percent Time in Range 70-180mg/dL Over 16 Week Trial Period — 67; 55 Percentage of Time
Phase 3 N=122 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
Prostate Adenocarcinoma
Primary: Number of Tumor Lesions Detected by 68Ga-RM2 MRI vs 68Ga-RM2 PET/MRI — 92; 127 number of tumor lesions
N/A N=284 Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer
Pancreatic Carcinoma
Primary: Number of Serious Pre-operative, Operative and Post-operative Adverse Events to 120 Days Post Randomization or to 30 Days Post Surgery, Whichever Comes Last — 40; 36…